Another global health crisis is gaining momentum. We need to be prepared.

March 29, 2026 - 02:55

While the world remains vigilant against known pandemic threats, a silent but relentless crisis is gaining momentum in the background: antimicrobial resistance (AMR). Often termed the "silent pandemic," AMR occurs when bacteria, viruses, fungi, and parasites evolve to withstand the medicines designed to kill them, rendering standard treatments ineffective and leading to difficult-to-cure infections.

The pipeline for new antibiotics has been dangerously dry for decades, a market failure driven by the high cost of development and the necessary conservation of new drugs as last-resort options. In a significant move to address this, the proposed PASTEUR Act seeks to fundamentally reshape the economic model for antibiotic development. The legislation would establish a subscription-style agreement between the federal government and pharmaceutical companies. Under this model, the government would provide a guaranteed annual payment to successful developers of critically needed novel antimicrobials, irrespective of the volume used. This "pull incentive" aims to ensure a steady supply of new, effective treatments are available when needed, while decoupling company revenue from the quantity of antibiotics sold.

Public health experts warn that without such innovative financial mechanisms and a concerted global effort to steward existing drugs and foster new ones, routine medical procedures, from surgeries to cancer chemotherapy, could become far more dangerous. The rise of untreatable infections poses a fundamental threat to modern medicine, making proactive investment and policy action not just prudent, but essential for future health security.